Clinical trials: Hematology
Leukemia
Symptom Burden in Chronic Myeloid Leukemia (CML)
Objectives: The objective of this study is to measure and delineate the symptom burden experienced by patients with chronic myeloid leukemia (CML). The Primary Aim is to develop and validate an M. D.
- Trial name
- NCT01046305
- Testing
- Interview & Questionnaires, Rating Questionnaire, MDASI-CML Questionnaire
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Project Affinity: Excess Cancer Blood Testing
Study investigating cancer blood samples on an iterative measurement systme
- Trial name
- NCT04724005
- Testing
- No drug
- Where
- United Kingdom
- Volunteers
- 613 people
- Sponsor
- Entia Ltd
Cold Agglutinin Disease
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion
The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants…
- Trial name
- Cadenza (NCT03347422)
- Testing
- sutimlimab (BIVV009)
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 42 people
- Sponsor
- Bioverativ, a Sanofi company
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT06592222
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Overweight, Nutritional Deficiency
The PROTEIN Project
New advances in information computer technology and artificial intelligence (AI) offer the possibility to create a personalized tool and support system for healthy living and eating, and this is the principal objective of the…
- Conditions
- Overweight, Nutritional Deficiency, Poor Nutrition, Iron-deficiency
- Trial name
- PROTEIN (NCT04829851)
- Testing
- PROTEIN Mobile App, Expert Dashboard
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
- Trial name
- NCT02629692
- Testing
- Vodobatinib (K0706) capsules
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 124 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Leukemia, Myelodysplastic Syndromes
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00003336
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia
CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA
This study aimed to explore the efficacy and safety of cyclosporine (CsA) +eltrombopag (EPAG)/hetrombopag (HPAG)+romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe…
- Trial name
- NCT07558434
- Testing
- Cyclosporine (CsA), thrombopoietin receptor agonist (TPO-RA), Romiplostim N01
- Volunteers
- 43 people
- Sponsor
- Peking Union Medical College Hospital
Placental Transfusion
Delayed Cord Clamping and Use of Oxytocin
The purpose of this study is to determine if oxytocin administration immediately after delivery of the infant modifies the volume of placental transfusion in healthy term infants.
- Trial name
- NCT02618499
- Testing
- Timing of administration of post partum Oxytocin
- Where
- Argentina
- Volunteers
- 180 people
- Sponsor
- Fundacion para la Salud Materno Infantil
Multiple Myeloma
GMMG-HD11/DSMM XXI/64007957MMY3010
This is an open-label, randomized interventional multicenter Phase 3 clinical trial to investigate the efficacy and safety of Tec-DRd induction therapy and fixed-duration Tec-D maintenance post ASCT in adult participants with TE…
- Trial name
- AugMMent (NCT07671287)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Volunteers
- 399 people
- Sponsor
- University of Heidelberg Medical Center
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid…
- Trial name
- NCT05241093
- Testing
- HYML-122; cytarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tarapeutics Science Inc.
Multiple Myeloma
Finistere Myeloma Observatory (OMYFIN)
Current molecular risk stratification of multiple myeloma (MM), based on the presence of t(4 ;14) and 17p deletion, cannot fully explain treatment outcome heterogeneity, as other features also predict prognosis.
- Trial name
- OMYFIN (NCT06552221)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Cancer, Chronic Myelomonocytic Leukemia
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Study and Dose Rationale The safety profile of clofarabine appears acceptable within the target populations studied to date in the clinical studies summarized in Section 2.3.
- Trial name
- NCT00708721
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Preventing Stroke in Sickle Cell Anaemia
Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial
Sickle cell anaemia (SCA) is a common hereditary haemoglobin disorder in Africa. World wide it is estimated that about 300,000 newborns are born every year. Of which 75% of them live in Sub-saharan Africa (SSA).
- Trial name
- PREST (NCT03666806)
- Testing
- Influenza vaccine
- Where
- Uganda
- Volunteers
- 150 people
- Sponsor
- Makerere University
Primary Immunodeficiencies, Inborn Errors of Metabolism
Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v.
- Conditions
- Primary Immunodeficiencies, Inborn Errors of Metabolism, Haemoglobinopathies, Bone Marrow Failure Syndromes
- Trial name
- NCT02349906
- Testing
- Treosulfan, Busilvex
- Where
- 21 sites in Czechia, Germany and 2 more
- Volunteers
- 106 people
- Sponsor
- medac GmbH
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
- Trial name
- NCT04678336
- Testing
- CART123 cells; cyclophosphamide; fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after…
- Trial name
- NCT06232044
- Testing
- Iberdomide, Belantamab Mafodotin, Dexamethasone
- Where
- 43 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
This is an open label, non-randomised, multicentre Phase I to determine the safety of tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their expansion/persistence with control EBV CTL in solid…
- Trial name
- ITREC (NCT03131934)
- Testing
- Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Hematological Malignancy (Leukemia- Lymphoma)
Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy
investigators aim to compare between anaesthetic regimens that included dual-agent (fentanyl and ketorolac) or (ketamine and ketorolac) analgesic therapy
- Trial name
- NCT03649334
- Testing
- ketamine-ketorolac, fentanyl- ketorolac
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.